Sars-CoV2 Clinical Trial
Official title:
Evaluation of the Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention in COVID-19 Intensive Unit Care Patients.
Patients with COVID-19 have special demographic characteristics including thromboembolic risk
factors .
The pharmacokinetics of enoxaparin administered subcutaneously in the intensive care unit
patient are not described.
Finally, given the lack of knowledge on the pharmacokinetic/pharmacodynamic properties of
enoxaparin in intensive care unit patients infected with SARS-CoV-2, we propose to conduct a
prospective multicenter cohort study to collect the biological data necessary for its study.
D-dimers greater than 1 μg/mL are a prognostic factor for 28-day mortality (odds ratio=18,
2-128). The use of preventive doses of enoxaparin (4,000 to 6,000 anti-Xa per day) or
unfractionated heparin (10,000 to 15,000 IU per day) has been associated with a reduction in
mortality of approximately one-third in patients with D-dimer levels greater than 3 μg/mL or
those with sepsis-induced coagulopathy (SIC (sepsis-induced coagulopathy) score > 4)
For the intensive care unit patient, the preventive enoxaparin dosages were increased to
4,000 anti-Xa IU twice daily and to 6,000 anti-Xa IU twice daily if the patient weighs more
than 120 kg. Curative treatment is even proposed in cases of marked inflammatory syndrome
and/or hypercoagulability (e.g. fibrinogen > 8 g/L or D-Dimer > 3 μg/mL or 3000 ng/mL) even
without symptomatic thrombosis.
Given the lack of data on the use of these high "prophylactic" doses of enoxaparin, it is
proposed that anti-Xa activity be monitored after the 3rd injection, and then regularly in
the event of renal failure (because LMWHs are renally eliminated), to look for overdosage
exposing a higher risk of bleeding. It is also proposed to regularly monitor (at least every
48 hours) the hemostasis of patients in search of multivisceral failure, or of coagulopathy
of consumption which will require a re-evaluation of the heparin therapy dosage, these events
being associated with an increased risk of haemorrhage.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04446065 -
Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers
|
Phase 2/Phase 3 | |
Completed |
NCT04419025 -
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
|
Phase 2 | |
Not yet recruiting |
NCT04400019 -
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
|
Phase 2/Phase 3 | |
Completed |
NCT04463004 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
|
Phase 2 | |
Completed |
NCT04446429 -
Anti-Androgen Treatment for COVID-19
|
N/A | |
Completed |
NCT04402957 -
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
|
Phase 2 | |
Recruiting |
NCT04581148 -
SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)
|
||
Recruiting |
NCT04441372 -
Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
|
||
Completed |
NCT04530604 -
Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
|
Phase 1 | |
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
Active, not recruiting |
NCT04635605 -
Methylene Blue Treatment of COVID-19
|
Phase 2 | |
Recruiting |
NCT04395599 -
Risk of Air Contamination During Visceral Surgery in COVID19 Patients
|
N/A | |
Recruiting |
NCT04472585 -
Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04411433 -
Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19
|
Phase 3 | |
Completed |
NCT04359706 -
Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
|
||
Recruiting |
NCT04395794 -
SARS-CoV-2 Disguise Study
|
||
Completed |
NCT04386551 -
Detection of COVID-19 in Saliva Collection
|
||
Recruiting |
NCT04403269 -
NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE
|
Phase 2 | |
Withdrawn |
NCT04379492 -
A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19
|
Phase 2 | |
Completed |
NCT04366934 -
Study of the Pathogenesis of Olfactory Disorders in COVID-19
|